Trial
NCT00868855
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Vanderbilt University
Collaborators
—
Condition
Coronary Artery Disease
Intervention
Bradykinin
Why stopped
poor enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-01